Results 311 to 320 of about 119,519 (336)

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire   +2 more sources

Malignancy and Janus Kinase Inhibition

Rheumatic Disease Clinics of North America, 2017
The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population.
Padmapriya, Sivaraman, Stanley B, Cohen
openaire   +2 more sources

Negative Regulation of Janus Kinases

Cell Biochemistry and Biophysics, 2001
The precise regulation of both the magnitude and the duration of Janus kinase (JAK) catalytic activity is essential for the cytokine orchestration of many biological processes, and the dysregulation of JAK activity has pathological implications.
R J, Duhé, L H, Wang, W L, Farrar
openaire   +2 more sources

Janus kinase inhibitors for alopecia areata

Journal of the American Academy of Dermatology, 2023
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and ...
Brett A, King, Brittany G, Craiglow
openaire   +2 more sources

Janus Kinase Inhibitors

2017
To control gene expression, cytokines and other extracellular molecules utilize the Janus kinase (JAK) and signal transducers and activators of transcription (STAT). Dysregulation of the JAK-STAT pathway has been implicated in a myriad of inflammatory and hematologic disorders.
Andrew Kim, Bruce Strober
openaire   +1 more source

Mapping the kinase domain of janus kinase 3

Bioorganic & Medicinal Chemistry Letters, 2003
The utilization and impact of parallel synthesis on lead exploration around initial hit oxindole (1) are described. The emergent SAR, analogue design and functional impact will also be detailed.
Christopher, Adams, David J, Aldous, Shelley, Amendola, Paul, Bamborough, Colin, Bright, Sarah, Crowe, Paul, Eastwood, Garry, Fenton, Martyn, Foster, Trevor K P, Harrison, Sue, King, Justine, Lai, Christopher, Lawrence, Jean-Philippe, Letallec, Clive, McCarthy, Neil, Moorcroft, Kenneth, Page, Sudha, Rao, Jane, Redford, Shazia, Sadiq, Keith, Smith, John E, Souness, Sukanthini, Thurairatnam, Mark, Vine, Barry, Wyman   +24 more
openaire   +2 more sources

[Janus kinase inhibitors].

Zeitschrift fur Rheumatologie, 2022
In 2017 the first Janus kinase (JAK) inhibitors were approved for the treatment of rheumatoid arthritis in Germany. The mode of action of JAK inhibitors differs from biologicals, as multiple cytokines are inhibited. In comparison with the treatment with biologicals, JAK inhibitors have the advantage of oral application, three of the four currently ...
openaire   +1 more source

[Janus kinase inhibitors].

Zeitschrift fur Rheumatologie, 2013
Janus protein tyrosine kinase (JAK) inhibitors are new therapeutic targets in the treatment of rheumatoid arthritis. Tofacitinib has shown good clinical efficacy in phase II and III studies with American College of Rheumatology (ACR) 20 response rates over 50% for monotherapy and in combination with methotrexate (MTX).
E, Ostermeier, P, Roll, H-P, Tony
openaire   +1 more source

The many faces of Janus kinase

Biochemical Pharmacology, 2012
Janus kinases have proved to be essential for many immunological processes but there is growing evidence that they also play a critical role in pathogenesis of many diseases including inflammatory diseases and cancer where they promote multiple steps of tumorigenesis.
Matthew M, Seavey, Pawel, Dobrzanski
openaire   +2 more sources

Janus kinases in cytokine signalling

Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 1996
Hematopoiesis is largely regulated by the binding of cytokines to receptors of the cytokine receptor superfamily. Although lacking catalytic domains, members of the cytokine receptor superfamily mediate ligand dependent activation of tyrosine phosphorylation which is critical for all receptor functions.
openaire   +2 more sources